MUNICH — Atorvastatin reduced the risk of major cardiovascular (CV) events, predominantly nonfatal events, by 30% compared with placebo in adults aged 70 years or older without known cardiovascular disease, diabetes, or dementia in the large randomized STAREE trial. However, nearly 6 years of treatment did not significantly improve disability-free survival — a composite of …
Read More
Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE
